Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences

BOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today announced that the company will present preclinical data on its conditionally active immuno-oncology programs at upcoming scientific conferences.

Details of the company’s presentations are as follows:    

• Keystone Symposia’s Cancer Immunotherapy: Beyond Immune Checkpoint Blockade and Overcoming Resistance
  
  Title: VISTA checkpoint targeting by SNS-101, a pH-selective antibody with enhanced safety and pharmacokinetic profiles, alters the tumor microenvironment and overcomes immune checkpoint inhibitor resistance  
  Presenter: Edward van der Horst, Ph.D., Chief Scientific Officer  
  Session: Progress in Drugging the TIGIT and VISTA Pathways  
  Date and time: Tuesday, March 19, 2024, 3 – 4:30 p.m. PT 
  
  Material from the presentation will also be presented in a poster at the conference, as detailed:  
  Poster Number: 3021 
  Session: Poster Session 3 
  Date and time: Wednesday, March 20, 2024, at 7:30 p.m. PT
  
  
• American Association for Cancer Research (AACR) Annual Meeting 2024
  
  Title: Conditionally active CD28xVISTA bispecific antibodies induce myeloid-driven tumor-specific T-cell co-stimulation for improved cancer immunotherapy
  Presentation Type: Poster Presentation
  Session Category: Immunology
  Session Title: Immune Modulation Employing Agonist or Co-Stimulatory Approaches
  Date and Time: Tuesday, April 9, 2024, 1:30 p.m. - 5:00 p.m. PT
  Location: Poster Section 3
  Abstract Number: 5294
  

About Sensei Biotherapeutics 
Sensei Biotherapeutics (Nasdaq: SNSE) is a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. Sensei’s lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. The company is also developing SNS-102, a conditionally active monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4); SNS-103, a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), also known as CD39; and SNS-201, a conditionally active VISTAxCD28 bispecific antibody consisting of a CD28 agonist arm and a pH-sensitive anti-VISTA arm. For more information, please visit www.senseibio.com, and follow the company on X @SenseiBio and LinkedIn.